FindTrial
Sign In

Establishment of a Specialized Database for Double-Filtration Plasmapheresis in the Treatment of Autoimmune Encephalitis and Research on Optimized Treatment Strategies

Establishment of a Specialized Database for Double-Filtration Plasmapheresis in the Treatment of Autoimmune Encephalitis and Research on Optimized Treatment Strategies - A Clinical Observation and Treatment Optimization Study on Double-Filtration Plasmapheresis for Autoimmune Encephalitis

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600124605
Enrollment
Unknown
Registered
2026-05-14
Start date
2026-05-25
Completion date
Unknown
Last updated
2026-05-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Autoimmune Encephalitis

Interventions

Double Filtration Plasmapheresis:None

Sponsors

Renji Hospital, Shanghai Jiao Tong University School of Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
12 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Age >= 12 years. 2. Diagnosed with Autoimmune Encephalitis (AiE) according to the 2016 diagnostic criteria (established by Graus et al.). 3. Patients undergoing double-filtration plasmapheresis and/or combined with other immunotherapies. 4. Signed the Informed Consent Form (for the prospective study component).

Exclusion criteria

Exclusion criteria: 1. Severe cardiac, hepatic, or renal insufficiency; cachexia; or severe systemic disease. 2. Active infection or bleeding tendency. 3. Pregnant or lactating women. 4. Allergy to medications associated with DFPP treatment. 5. Inability to cooperate with follow-up procedures.

Design outcomes

Primary

MeasureTime frame
changes of modified Rankin Scale;changes of clinical assessment scale for autoimmune encephalitis;Proportion of patients with treatment response in the overall population and subgroups;—

Secondary

MeasureTime frame
The proportion of patients with a ?mRS of >=1 point or an mRS of =1 point;Recurrence-free rate;Annual recurrence rate;Time to first recurrence;Changes in immune-related laboratory parameters;Changes in scores on the Cognitive-Emotional-Sleep-Related Functioning Scale;Changes in antibody titers;—

Countries

China

Contacts

Public ContactYong Hao

Renji Hospital, Shanghai Jiao Tong University School of Medicine

yhao23@126.com+86 189 1765 9576

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: May 22, 2026